Recent News

• 08.11.2025 - Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
• 08.11.2025 - Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
• 06.30.2025 - Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
• 06.30.2025 - Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
• 06.11.2025 - Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
• 06.11.2025 - Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
• 06.05.2025 - Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
• 06.05.2025 - Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
• 05.13.2025 - Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.13.2025 - Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 06.12.2025 - 8-K Current report
• 06.12.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.11.2025 - 8-K Current report
• 06.06.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 04.30.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]